• Normalized FFO per Share: $3.19 for full-year 2024, a 7% year-over-year increase.
• SHOP Same-Store Cash NOI Growth: Nearly 16% for 2024.
• Same-Store Occupancy Growth: Increased by 300 basis points year-over-year.
• Annualized EBITDA: $2.2 billion by year-end 2024.
• Total Company Same-Store Cash NOI Growth: Nearly 8% for 2024.
• Senior Housing Investments: Over $2 billion completed in 2024.
• Net Debt-to-EBITDA: 6.0 times by Q4 2024, a 90-basis-point improvement year-over-year.
• Liquidity: Nearly $4 billion at the end of 2024.
• 2025 Guidance for Normalized FFO per Share: $3.35 to $3.46, representing 7% growth at the midpoint.
• 2025 Total Company Same-Store Cash NOI Growth Guidance: Approximately 6.75% year-over-year growth at the midpoint.

• Warning! GuruFocus has detected 9 Warning Signs with VTR.

Release Date: February 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Ventas Inc (NYSE:VTR) delivered a full-year normalized FFO per share of $3.19, exceeding the high end of their guidance range.
• The company achieved a 16% growth in SHOP same-store cash NOI, marking the third consecutive year of double-digit growth.
• Ventas Inc (NYSE:VTR) completed over $2 billion in accretive investments focused on senior housing, enhancing their portfolio and growth prospects.
• The company increased its quarterly dividend to stockholders by 7%, reflecting confidence in future performance.
• Ventas Inc (NYSE:VTR) improved its leverage, entering its long-term targeted range by year-end, and achieved nearly 8% total company same-store cash NOI growth in 2024.

Negative Points

• The medical-office-building segment experienced some occupancy declines, raising concerns about future performance.
• Despite strong performance, the company faces potential risks from changes in NIH funding, which could impact their research portfolio.
• The competitive environment for senior housing acquisitions is intensifying, with more players entering the market.
• The company anticipates higher net interest expenses in 2025 due to refinancing maturing debt at higher rates.
• There is a reliance on a successful key selling season for SHOP growth, which introduces uncertainty in achieving projected occupancy gains.

Q & A Highlights

Q: Can you explain the trajectory for the medical-office-building side, given the occupancy declines in the quarter but strong same-store NOI growth in 2025 guidance? A: Peter Bulgarelli, Executive Vice President, President and CEO of Lillibridge Healthcare Services, Inc, explained that they did more leasing in 2024, with a 15% increase over the prior year. As these leases come online, they expect to see meaningful results in NOI. For 2025, they have already completed 34% of their leasing plan, which supports expected occupancy gains and corresponding NOI growth.

Q: What strategic actions is Ventas taking to capitalize on demographic tailwinds in senior housing? A: J. Justin Hutchens, Executive Vice President - Senior Housing, Chief Investment Officer, stated that Ventas OI focuses on markets, assets, and operators, using data to make informed investment and disposition decisions. This hyper-local focus ensures sustained growth opportunities and positions Ventas well for future demographic trends.

Q: Can you discuss the return profile of your acquisition strategy targeting more stabilized assets? A: J. Justin Hutchens explained that Ventas is investing in high-quality assets that offer both yield and growth. These assets are typically 90% occupied, with opportunities for occupancy and pricing growth. The unlevered IRRs are in the low to mid-teens, driven by growth rather than cap rate compression.

Q: How does the competitive environment for acquisitions look, and what is Ventas' strategy for the second half of 2025? A: J. Justin Hutchens noted that the pipeline is larger than last year, with more competition and new players entering the market. Ventas' competitive advantage lies in its platform, data analytics, and operator relationships, allowing it to manage a diverse portfolio effectively.

Q: What are the risks around NIH funding changes, and how might they impact Ventas' assets? A: Debra Cafaro, Chairman and CEO, mentioned that while there is some noise around NIH grants, any changes have been halted, and grant recipients should continue to receive full funding. The US leads in biomedical research, and Ventas' research portfolio is well-positioned with diverse funding sources.

Q: What is the strategy for the $200 million capital recycling via dispositions? A: Debra Cafaro confirmed that the strategy involves disposing of skilled nursing facilities acquired previously, with about $150 million pending. The capital will be recycled into senior housing investments.

Q: How is Ventas addressing labor market challenges in the SHOP business? A: J. Justin Hutchens stated that the labor market has been favorable, with strong hiring and retention trends. The expense forecast assumes current inflationary projections, with a 5% increase accounting for wage increases and occupancy volume impact.

Q: What is the outlook for RevPOR growth in senior housing, given the 7% January rent increases? A: J. Justin Hutchens explained that the US saw an 8% rent increase, similar to last year. RevPOR growth is influenced by factors such as new move-ins and level of care revenue, with opportunities for improvement as occupancy and pricing power increase.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.